Topiramate: Side Effects, Uses & Monitoring
Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures.
- Data source
- FDA labeling via NIH DailyMed (label b8b097e0…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Paresthesia | 40% |
| Fatigue | 30% |
| Upper respiratory tract infection | 18% |
| Weight decrease | 16% |
| Somnolence | 15% |
| Dizziness | 14% |
| Anorexia | 14% |
| Difficulty with memory | 14% |
| Injury | 14% |
| Speech disorders/related speech problems | 13% |
| Vision abnormal | 13% |
| Nausea | 12% |
| Nystagmus | 11% |
| Personality disorder (behavior problems) | 11% |
| Difficulty with memory nos | 10% |
| Language problems | 10% |
| Diplopia | 10% |
| Insomnia | 9% |
| Depression | 9% |
| Fever | 9% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Monotherapy Epilepsy Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials. Adjunctive Therapy Epilepsy Topiramate tablets are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.
Conditions associated with Topiramate in labeling
Frequently Asked Questions
What is Topiramate used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Topiramate?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Topiramate. Individual risk varies.
Does Topiramate require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Topiramate.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.